65,437 trials
Hepatitis B, Chronic
Primary: Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72 — 0 percentage of participants
Diabetic Neuropathy, Painful
Primary: Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks — -2.08; -2.22; -2.45; -2.42 units on a scale
Diabetes
Primary: Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method — 180; 179; 172…
Nephrolithiasis · Hyperoxaluria · Crohn's Disease
Primary: Change in 24-hour Urinary Supersaturation for Calcium Oxalate — 1.40; 1.36; 1.42 KJoules/mol — p=0.3
Asthma
Primary: Time to Treatment Failure (Measured in Days) — 196.9; 225.2; 182.3 days
Nondependent Opioid Abuse, Episodic
Primary: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours — 88.3; 100.3; 124.7 hrs*mm — p=<0.0001
Prostate Cancer
Primary: Overall Survival — 24.5; 22.5 months
Diabetes
Primary: Percent of Fingerstick Blood Glucose (BG) Results Within +/-20%(>=75 mg/dL) and Within +/- 15mg/dL (<75 mg/dL) of Laboratory Glucose Method — 95.5 Percentage of BG test…
Healthy Subjects
Primary: Comparison of Least Squares (LS) Mean Changes From Baseline in Population-based Corrected QT Intervals (QTcP) Between Exenatide and Placebo on Day 1 Averaged Over 1300h…
Prostate Cancer
Primary: Overall Survival — 20.0; 19.2 Months
Psoriasis Chronic
Primary: Psoriasis Area and Severity Index (PASI) Score — 15.5; 7.6; 2.5; 2.0 units on a scale
Alcoholism · Alcohol Abuse
Primary: Percent Heavy Drinking Days — 37.1; 37.9 percentage of heavy drinking days
Myelofibrosis
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001
Anemia · Chronic Renal Failure · Chronic Kidney Disease
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 9.34; 9.20; 9.07; 11.45 g/dL
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 7; 7; 2; 0 Subjects